In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative option. However, the introduction of novel therapies including T-cell engaging therapies has sparked a paradigm shift in R/R LBCL/DLBCL management.
In this transforming landscape, bispecific antibodies (BsAbs) stand out as a remarkable addition. They offer readily available, "off-the-shelf" options that do not require a manufacturing process tailored to each patient, with the advantage of lower rates of severe side effects compared to CAR T-cell therapy, making them a promising choice, particularly for older patients and those with late-stage disease.
This educational activity will assist community oncology practices as they adopt these promising treatments and ensure they are optimally incorporated into clinical practice, while engaging in shared decision-making with patients. This activity will review the mechanisms of action and delivery methods of different CD20 X CD3 bispecific antibodies, the latest clinical trial evidence and guideline recommendations for bispecific antibodies targeting CD20 and CD3, and strategies for adverse event management related to the use of CD20 X CD3 bispecific antibodies. Expert thought leaders will not only present recent and emerging clinical data and challenging case study examples, but also offer expert insights and advice based on their own real-world clinical practice experiences regarding the management and treatment of R/R DLBCL/LBCL and appropriate selection and integration of novel therapies.
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
This educational activity will assist community oncology practices as they adopt bispecific antibodies for the treatment of patients with relapsed/refractory LBCL/DLBCL to deliver quality evidence-based care.
This broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Overview
Program Schedule*
- Activity Introduction
- Factors that differentiate CD20 X CD3 bispecific antibodies
- Clinical efficacy/safety data of CD20 X CD3 bispecific antibodies
- Patient selection, multidisciplinary treatment plans, and sequencing implications
- Team-based management strategies for adverse events with CD20 X CD3 bispecific antibodies
- Practical Application: Case-based Learning Lab
- Activity Conclusion and Q&A
*Subject to change
Disclosure of Relevant Financial Relationships
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months.
Caron A. Jacobson, MD, reported a financial interest/relationship or affiliation in the form of Consultant; Kite / Gilead, AbbVie, Abintus Bio, ADC Therapeutics, Bristol-Myers Squibb / Celgene, Caribou Bio, Daiichi-Sankyo, Inc., ImmPACT Bio, Instil Bio, Ipsen Pharmaceuticals, Miltenyi, Morphosys, Novartis Pharmaceuticals Corporation & Synthekine. Received income in any amount from; Sana, Appia & Janssen Oncology.
The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Wilma Guerra, BELS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; Adrienne N. Nedved, PharmD., MPA., BCOP; and Dee Morgillo, MEd., MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Geist, MD, reported a financial interest/relationship or affiliation during the past 24 months as a past employee of Fresenius Medical Care. This relationship has ended. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate the novel mechanism of action of CD20 X CD3 bispecific antibodies, how these agents are delivered, and the differences among and between these agents and CAR T-cell therapies for R/R DLBCL/LBCL
- Summarize updated clinical efficacy and safety data associated with the use of CD20 X CD3 bispecific antibodies for R/R DLBCL/LBCL
- Develop team-based, multidisciplinary treatment plans that involve shared decision-making tactics for selected patients with R/R DLBCL/LBCL and include CD20 X CD3 bispecific antibodies based on clinical evidence, disease- and patient-related characteristics, and patient goals and preferences
- Integrate team-based management and care coordination strategies for adverse events, including CRS and ICANS, related to the use of CD20 X CD3 bispecific antibodies for R/R LBCL/DLBCL
Target Audience
Community-based oncologists, hematologists, hematology oncologists, nurse practitioners, pharmacists (APPs), and other community-based practicing healthcare professionals with a role of treating and managing patients with R/R DLBCL/LBCL.
Accreditation and Credit Designation Statements
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 02/28/2026. PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-24-009-L01-P.Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour. Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Laboratory Professionals
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.Commercial Support
This activity is supported by an educational grant from Genmab US, Inc., who has had no influence on, control of, nor input into the development or performance of the activity.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information.AXIS Contact Information
For information about the certification of this activity, please contact AXIS at info@axismeded.com.
There is no fee for this educational activity.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Overview
In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative option. However, the introduction of novel therapies including T-cell engaging therapies has sparked a paradigm shift in R/R LBCL/DLBCL management.
In this transforming landscape, bispecific antibodies (BsAbs) stand out as a remarkable addition. They offer readily available, "off-the-shelf" options that do not require a manufacturing process tailored to each patient, with the advantage of lower rates of severe side effects compared to CAR T-cell therapy, making them a promising choice, particularly for older patients and those with late-stage disease.
This educational activity will assist community oncology practices as they adopt these promising treatments and ensure they are optimally incorporated into clinical practice, while engaging in shared decision-making with patients. This activity will review the mechanisms of action and delivery methods of different CD20 X CD3 bispecific antibodies, the latest clinical trial evidence and guideline recommendations for bispecific antibodies targeting CD20 and CD3, and strategies for adverse event management related to the use of CD20 X CD3 bispecific antibodies. Expert thought leaders will not only present recent and emerging clinical data and challenging case study examples, but also offer expert insights and advice based on their own real-world clinical practice experiences regarding the management and treatment of R/R DLBCL/LBCL and appropriate selection and integration of novel therapies.Program Schedule*
- Activity Introduction
- Factors that differentiate CD20 X CD3 bispecific antibodies
- Clinical efficacy/safety data of CD20 X CD3 bispecific antibodies
- Patient selection, multidisciplinary treatment plans, and sequencing implications
- Team-based management strategies for adverse events with CD20 X CD3 bispecific antibodies
- Practical Application: Case-based Learning Lab
- Activity Conclusion and Q&A
*Subject to change
Disclosure of Relevant Financial Relationships
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months.
Caron A. Jacobson, MD, reported a financial interest/relationship or affiliation in the form of Consultant; Kite / Gilead, AbbVie, Abintus Bio, ADC Therapeutics, Bristol-Myers Squibb / Celgene, Caribou Bio, Daiichi-Sankyo, Inc., ImmPACT Bio, Instil Bio, Ipsen Pharmaceuticals, Miltenyi, Morphosys, Novartis Pharmaceuticals Corporation & Synthekine. Received income in any amount from; Sana, Appia & Janssen Oncology.
The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Wilma Guerra, BELS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; Adrienne N. Nedved, PharmD., MPA., BCOP; and Dee Morgillo, MEd., MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Geist, MD, reported a financial interest/relationship or affiliation during the past 24 months as a past employee of Fresenius Medical Care. This relationship has ended. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate the novel mechanism of action of CD20 X CD3 bispecific antibodies, how these agents are delivered, and the differences among and between these agents and CAR T-cell therapies for R/R DLBCL/LBCL
- Summarize updated clinical efficacy and safety data associated with the use of CD20 X CD3 bispecific antibodies for R/R DLBCL/LBCL
- Develop team-based, multidisciplinary treatment plans that involve shared decision-making tactics for selected patients with R/R DLBCL/LBCL and include CD20 X CD3 bispecific antibodies based on clinical evidence, disease- and patient-related characteristics, and patient goals and preferences
- Integrate team-based management and care coordination strategies for adverse events, including CRS and ICANS, related to the use of CD20 X CD3 bispecific antibodies for R/R LBCL/DLBCL
Target Audience
Community-based oncologists, hematologists, hematology oncologists, nurse practitioners, pharmacists (APPs), and other community-based practicing healthcare professionals with a role of treating and managing patients with R/R DLBCL/LBCL.
Accreditation and Credit Designation Statements
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 02/28/2026. PAs should only claim credit commensurate with the extent of their participation.Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-24-009-L01-P.Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour. Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Laboratory Professionals
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.Commercial Support
This activity is supported by an educational grant from Genmab US, Inc., who has had no influence on, control of, nor input into the development or performance of the activity.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information.AXIS Contact Information
For information about the certification of this activity, please contact AXIS at info@axismeded.com.
There is no fee for this educational activity.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
CME/CEChairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
0.25 credits
Jorge E. Cortes, MD
0.25 creditsRedefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
CME/CERedefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
0.50 creditsSagar Lonial, MD, FACP
Meghan Berkenstock, MD
Saad Z. Usmani, MD, MBA, FACP
0.50 creditsChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
CME/CEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
0.50 creditsMatthew S. Davids, MD, MMSc
0.50 creditsChairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
CME/CEChairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
0.50 creditsJoshua E. Reuss, MD
0.50 credits